464280.KQ
Tdspharm
KOE · Healthcare · Drug Manufacturers - General · KR
KRW 5,820.00
−1.02%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 32.9B | 27.6B | 27.5B | 30.0B | 25.6B |
| Cost of Revenue | 23.9B | 20.3B | 19.8B | 22.1B | 19.4B |
| Gross Profit | 9.0B | 7.3B | 7.7B | 7.8B | 6.2B |
| Operating Expenses | |||||
| R&D Expense | 633.4M | 665.9M | 622.5M | 441.2M | 478.8M |
| SG&A Expense | 1.9B | 737.7M | 812.2M | 738.2M | 644.5M |
| General & Admin Expense | 273.3M | 337.3M | 297.6M | 249.5M | 448.7M |
| Selling & Marketing Expense | 277.3M | 400.3M | 514.5M | 488.6M | 195.8M |
| Other Expenses | 1.6B | 2.1B | 2.6B | 1.7B | 1.3B |
| Total Operating Expenses | 3.5B | 3.5B | 4.0B | 2.9B | 2.4B |
| Cost and Expenses | 27.3B | 23.9B | 23.8B | 25.0B | 21.8B |
| Operating Income (EBIT) | 5.6B | 3.8B | 3.7B | 5.0B | 3.8B |
| Non-Operating | |||||
| Interest Income | 801.4M | 903.8M | 846.7M | 519.5M | 198.5M |
| Interest Expense | 291.0M | 237.6M | 267.7M | 301.5M | 220.6M |
| Net Interest Income | 510.4M | 666.2M | 579.0M | 218.0M | (22.2M) |
| Other Non-Op Income/Expense | 516.4M | 1.2B | 482.0M | 472.7M | 65.4M |
| Non-Operating Income (excl Interest) | (398.9M) | (1.4B) | (749.7M) | (774.1M) | (286.1M) |
| EBT (Pre-Tax Income) | 6.2B | 5.0B | 4.2B | 5.5B | 3.8B |
| Income Tax Expense | 1.0B | 698.1M | 493.9M | 801.1M | 390.4M |
| Bottom Line | |||||
| Net Income | 5.2B | 4.3B | 3.7B | 4.7B | 3.5B |
| Earnings from Cont. Ops | 5.2B | 4.3B | 3.7B | 4.7B | 3.5B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 5.2B | 4.3B | 3.7B | 4.7B | 3.5B |
| Per Share | |||||
| Basic EPS | ₩974 | ₩808 | ₩703 | ₩1,101 | ₩811 |
| Diluted EPS | ₩974 | ₩808 | ₩703 | ₩1,101 | ₩811 |
| Revenue Per Share | ₩6,222 | ₩5,221 | ₩5,203 | ₩7,057 | ₩6,005 |
| Shares | |||||
| Basic Shares Outstanding | 5.3M | 5.3M | 5.3M | 4.3M | 4.3M |
| Diluted Shares Outstanding | 5.3M | 5.3M | 5.3M | 4.3M | 4.3M |
| Profitability Metrics | |||||
| EBITDA | 6.4B | 5.9B | 5.1B | 6.8B | 5.3B |
| D&A | 723.4M | 699.6M | 668.6M | 1.0B | 1.3B |
| EBIT | 5.8B | 5.2B | 4.5B | 5.8B | 4.1B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026